Recent animal research, using rats, suggests there may be a cheap and non-invasive method of detecting Parkinson’s Disease early – before symptoms develop – by identifying changes in the eye.
The same study also offers early evidence for a newly formulated version of the anti-diabetic drug Rosiglitazone as a promising neuroprotective therapeutic for Parkinson’s Disease (similarly assessed in terms of changes to retinal thickness, again in rats at least).
“Together, these findings suggest that retinal changes may be a good surrogate biomarker for PD, which may be used to assess new treatments both experimentally and clinically”.
Parkinson’s could potentially be detected by an eye test. London: BBC Health News, August 18th 2016.
This relates to:
Normando, EM. Davis, BM. [and] De Groef, L. [et al] (2016). The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain. Acta Neuropathologica Communications. August 18th 2016; 4(1): 86.